| John Morgan Sproul, PA | |
|
57 Beam Ln Ste 205, Fishersville, VA 22939-2350 | |
| (434) 243-7121 | |
| (434) 243-7122 |
| Full Name | John Morgan Sproul |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 12 Years |
| Location | 57 Beam Ln Ste 205, Fishersville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821393786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0110007872 (Virginia) | Secondary |
| 363A00000X | Physician Assistant | 0110007872 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Virginia Medical Center | Charlottesville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Virginia Physicians Group | 4880590728 | 1397 |
News Archive
The American Dental Association (ADA) is launching "Straight from the Mouth," a new video podcast series for the public, to provide oral health information in amusing three to five-minute Webisodes.
Bracelets and amulets are in the works at Dartmouth's Institute for Security, Technology, and Society (ISTS). Rather than items of mere adornment, the scientists and engineers are constructing personal mobile health (mHealth) devices-highly functional jewelry, as it were.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Morgan Sproul, PA Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | John Morgan Sproul, PA 57 Beam Ln Ste 205, Fishersville, VA 22939-2350 Ph: (434) 243-7121 |
News Archive
The American Dental Association (ADA) is launching "Straight from the Mouth," a new video podcast series for the public, to provide oral health information in amusing three to five-minute Webisodes.
Bracelets and amulets are in the works at Dartmouth's Institute for Security, Technology, and Society (ISTS). Rather than items of mere adornment, the scientists and engineers are constructing personal mobile health (mHealth) devices-highly functional jewelry, as it were.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
› Verified 6 days ago